Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Announces Results of 2026 Annual Meeting of Stockholders

Citius Pharmaceuticals, Inc. (“Citius” or “the Company”), a specialty pharmaceutical company listed on the Nasdaq Capital Market under the ticker symbol CTXR, has disclosed the results of its 2026 Annual Meeting of Stockholders held on April 6, 2026. The meeting addressed key matters of corporate governance and oversight that are important to current and prospective investors.

Key Points from the Report

• Director Elections: The shareholders voted on the election of directors to the Company’s Board. The report specifically names Leonard Mazur (CEO) and Carol Webb as directors up for re-election, with detailed voting results provided for their seats.
• Ratification of Independent Auditors: Stockholders ratified the selection of Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2026.
• Corporate Governance Status: Citius Pharmaceuticals is no longer an “Emerging Growth Company” as defined by SEC rules, which may impact its compliance obligations and investor perceptions.

Detailed Voting Results

Auditor Ratification: The appointment of Wolf & Company, P.C. as the independent auditor was ratified with the following votes:

• For: 8,593,946 shares
• Against: 855,866 shares
• Abstain: 673,867 shares
• Broker Non-Votes: None

Other Important Disclosures

• Regulatory Communications: The Company confirmed that this Form 8-K filing is not intended to satisfy written communications under Rule 425, nor does it constitute soliciting material under Rule 14a-12, or pre-commencement communications under Rules 14d-2(b) or 13e-4(c) of the Exchange Act.
• SEC Filings and Compliance: The Company remains fully compliant with Section 13 and 15(d) of the Securities Exchange Act of 1934, and its common stock continues to trade on the Nasdaq Capital Market.
• Corporate Structure: Citius Pharmaceuticals, Inc. is incorporated in Nevada and is headquartered at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016. The Company’s EIN is 27-3425913.
• Share Class: The only class of securities registered under Section 12(b) is “Common stock, \$0.001 par value,” trading under the symbol CTXR.

Potentially Price Sensitive & Shareholder-Relevant Information

• Leadership and Board Continuity: The re-election of Leonard Mazur, who also serves as CEO, and Carol Webb as directors, ensures continuity in leadership and corporate strategy, which may be viewed positively by the market.
• Stable Auditor Relationship: The ratification of Wolf & Company, P.C. as the independent auditor signals stability and continuity in financial oversight, reducing the risk of audit-related surprises for investors.
• Change in Regulatory Status: The loss of “Emerging Growth Company” status could impact financial reporting and compliance costs, as well as the Company’s eligibility for certain reduced-disclosure accommodations. This could affect investor expectations going forward.

Other Observations

• No new share classes or changes to capital structure were announced.
• No merger, acquisition, or other corporate actions were disclosed.
• No written communications, tender offers, or solicitation activities related to M&A were reported.

Conclusion

While no transformative events such as major M&A or product news were disclosed in this filing, the confirmation of leadership stability, auditor ratification, and a shift in regulatory status are all material updates that investors should note. These factors may contribute to share price stability, and the change in “Emerging Growth Company” status is noteworthy for valuation models and compliance expectations.

Disclaimer: This article is based on the official SEC Form 8-K filing by Citius Pharmaceuticals, Inc. dated April 6, 2026. It is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The author and publisher are not liable for any decisions made based on this information.

View Citius Pharmaceuticals, Inc. Historical chart here